Latest Content

Amber Carissa "A.C." Flynn details a case in her AAOpt 2026 poster that demonstrates successful ocular surface optimization for a patient with several eye conditions.

Kevin Chan, OD, MS, FAAO, FBCLA, IACMM, stated in his Rapid Fire lecture that high myopes shouldn't be counted out of orthokeratology treatment.

Maria Sampalis, OD, discusses her implementation of the EHR software Barti in her practice.

Mohammad Rafieetary, OD, FAAO, FORS, DipABO, ABCMO, details his AAOpt 2026 presentation "Photobiomodulation in Age-Related Macular Degeneration: Evidence, Mechanisms, and Clinical Integration."

Magdalena Stec, OD, FAAO, and Noreen Shaikh, OD, MEd, FAAO, gave an overview of current evidence-based myopia control treatments in part of their AAOpt 2026 session.

Eric Schmidt, OD, FAAO, presented his poster "Patient-Reported Blurred Vision Improvement with Cyclosporine 0.1%/PFBP in Dry Eye Disease with Severe Central Corneal Staining: Phase 3 Pool" at AAOpt 2026.

Aflibercept 8 mg cut RVO injections by up to 3 over 64 weeks in QUASAR, while a pair of additional posters show Amsler gaps in AMD and BRAO-linked stroke risk.

Host Hamza Shah, OD, MS, FAAO, is joined by Cory Lappin, OD, MS, FAAO, to discuss dynamic muscle stimulation for dry eye, spurred by a paper on improving blinking in dry eye patients.

A young woman had years of headaches, dizziness, and intolerance of her phone despite normal routine eye examinations. A modest prism gave her immediate relief.

Sherrol Reynolds, OD, FAAO, details her session "GLP-1RAs and Ocular Health: AOA Guidance for Optometric Practice 2025" during AAOpt 2026.

Phil Rainey, OD, MPH, FAAO, states that the recent parameter expansion of Johnson & Johnson's Acuvue Oasys Max 1-Day and Oasys 1-Day has been a game changer for his practice.

A pair of cases from Academy 2026 show scleral lens refits for severe keratoconus, one addressing focal corneal edema and one fitting around glaucoma tube shunts.

Nora Lee Cothran, OD, FAAO, reviews a study which found a statistically significant reduction in IOP in patients with open-angle glaucoma and ocular hypertension when switching to latanoprostene bunod.